DENVER –  Vaporox, Inc., a medical device company dedicated to healing chronic skin wounds, is proud to announce that they have joined the Catalyst HTI ecosystemin Denver, Colorado. “We chose to join Catalyst because of the concentration of medical expertise and the ability to meet and share ideas with both startups and mature companies in the industry,” said Alan Sage, CEO of Vaporox. “It is so great to be surrounded by so many other driven people developing products to improve patient lives.”

Vaporox has developed a patented and FDA-cleared technology called Vaporous Hyperoxia Therapy (VHT™), which accelerates the healing of 9 different types of wounds. For Example, chronic diabetic foot ulcers (DFUs), which are both painful and debilitating, generate annual healthcare costs around $15 billion/year in the U.S. alone. DFUs are the leading cause of non-traumatic lower extremity amputations in the US.

Learn more

Vaporox, a Denver based medical device startup, piqued investor interest at the recent “Angel Capital Summit 2019” sponsored by the Rockies Venture Club (RVC).  Vaporox then finished first in that conference’s “Venture Bucks” competition (see photo below), which bestows a coveted “People’s Choice” award for the best investment opportunity.

Vaporox’s technology, Vaperous Hyperoxia Therapy (“VHT”) is a breakthrough technology for healing skin wounds.  VHT employs ultrasonic waves to create an aqueous vapor containing an antimicrobial. VHT penetrates into the recesses of the wound, and ultimately through the cell walls.  VHT is both much more effective and more comfortable for patients than existing treatments.  In a clinical study, VHT healed 87% of diabetic foot ulcers (DFUs) that had defied the current “gold standard” of wound care.

Learn more